A powerful new drug combination—niraparib added to standard prostate cancer therapy—has been shown to significantly delay disease progression in men with specific DNA repair gene mutations. In the ...
Significant improvement in radiographic progression-free survival seen first in BRCA subgroup. (HealthDay News) — For patients with metastatic castration-sensitive prostate cancer (mCSPC) with ...
A U.S. FDA panel of independent experts beat back an effort by Pfizer (NYSE:PFE) to expand the patient population for its prostate cancer treatment Talzenna (talazoparib). Members of the Oncologic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results